EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy

Rebecca A Krukowski iD, Xin Hu iD, Sara Arshad, Janeane N Anderson iD, Edward Stepanski, Gregory A Vidal iD, Lee S Schwartzberg iD, Ilana Graetz iD

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci-24-00179 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Rebecca A Krukowski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, University of Virginia Comprehensive Cancer Center and School of Medicine, Charlottesville, VA. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer Survivors, Mobile Applications, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIMHD NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Oral adjuvant endocrine therapy (AET) reduces the risk of cancer recurrence and death for women with hormone receptor–positive (HR+) breast cancer. Because of adverse symptoms and socioecologic barriers, AET adherence rates are low. We conducted post hoc analyses of a randomized trial of a remote symptom and adherence monitoring app to evaluate characteristics associated with higher app use, satisfaction, and how app use was associated with AET adherence. METHODS Patients prescribed AET were randomly assigned to receive one of three intervention conditions: app, app + feedback, or enhanced usual care. Baseline and 6-month follow-up surveys, app use, and pillbox-monitored AET adherence data for app and app + feedback participants were used. Logistic regression evaluated the association between sociodemographic/clinical characteristics and app utilization and satisfaction, and how app use was associated with AET adherence (>80%). RESULTS Overall, 163 women with early-stage HR+ breast cancer were included; 35.0% had high app use (≥75% of weeks enrolled). No sociodemographic characteristics were associated with app use. Satisfaction with the app was higher among those who were younger (88.9% for age 31-49 years v 54.9% for age 65+ years, P < .001), identified as White (76.8% v 60.1% for Black, P = .045), had lower health literacy (85.4% v 68.2% with higher health literacy, P = .017), or were nonurban residents (85.7% v 68.6% for urban, P = .021). Most participants (90.3%) with high app use were AET-adherent compared with 66.8% for those with lower app use ( P < .001). CONCLUSION Use of a remote monitoring app was similar across sociodemographic characteristics, and more frequent app use was associated with a higher likelihood of 6-month AET adherence. Encouraging women to monitor medication adherence and communicate adverse symptoms could improve AET adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCancer SurvivorsMobile ApplicationsAntineoplastic Agents, HormonalDrug MonitoringHumansFemaleMiddle AgedChemotherapy, AdjuvantAgedAdult

Substanzen

Antineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Public Health Sciences, University of Virginia Comprehensive Cancer Center and School of Medicine, Charlottesville, VA.
  • Department of Radiation Oncology, Emory University, Atlanta, GA.
  • Department of Health Policy and Management, Emory University, Atlanta, GA.
  • Department of Community and Population Health, University of Tennessee Health Science Center, Memphis, TN.
  • Ovation.io, Cambridge, MA.
  • West Cancer Center and the Lee S. Schwartzberg Research Institute, Germantown, TN.

ORCID-Profile: Rebecca A Krukowski, Xin Hu, Janeane N Anderson, Gregory A Vidal, Lee S Schwartzberg, Ilana Graetz

Förderung

  • NCI NIH HHS
  • NIMHD NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Krukowski, R. A., Hu, X., Arshad, S., Anderson, J. N., Stepanski, E., Vidal, G. A., Schwartzberg, L. S., & Graetz, I. (2024). Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00179

Vancouver

Krukowski RA, Hu X, Arshad S, Anderson JN, Stepanski E, Vidal GA, et al. Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci-24-00179

BibTeX
@article{Krukowski2024,
  author = {Krukowski, Rebecca A and Hu, Xin and Arshad, Sara and Anderson, Janeane N and Stepanski, Edward and Vidal, Gregory A and Schwartzberg, Lee S and Graetz, Ilana},
  title = {Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci-24-00179}
}
Kostenlos starten →